

RECEIVED
TECH CENTER 1600/2900

02 FEB 27 AM 10:46

Patent Application
Docket No. NPB-100D5
Serial No. 09/970,558

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Dwayne Jones
Art Unit : 1614
Applicant(s) : Carver *et al.*
Serial No. : 09/970,558
Filed : October 4, 2001
For : Injectable Composition

Assistant Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:


In accordance with 37 CFR §1.97 and 1.98, Applicants would like to bring to the attention of the Examiner the documents listed on the attached form PTO-1449. Provided are copies of the Affidavit of Prof. Dr. Siegfried Blechert in support of the Opposer Teva Pharmaceuticals Ltd. which has filed an Opposition against Israeli Application No. 107776, a foreign counterpart of this application; and submissions of two opponents, BASF and Herr Frohwitter, who have opposed EPO Patent No. 0 674 510 (also a counterpart to this application); as well as the Preliminary View of the EPO Opposition Division in that opposition proceeding. Copies of all cited documents are enclosed.

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by provision of the foregoing statement.

RECEIVED
MAR 04 2002
TECH CENTER 1600/2900

Any additional fees as required by 37 CFR 1.16 or 1.17 should be charged to Deposit Account No. 19-0065.

Respectfully submitted,



Jeff Lloyd

Patent Attorney

Registration No. 35,589

Phone No.: 407-426-7500

Address : 2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606

JL/gm

Enclosure: Form PTO-1449

RECEIVED
MAR 04 2002
TECH CENTER 1600/2900